1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

New Market Study Published: Switzerland Pharmaceuticals & Healthcare Report Q2 2011

Recently published research from Business Monitor International, "Switzerland Pharmaceuticals & Healthcare Report Q2 2011", is now available at Fast Market Research

 
PRLog - Apr. 20, 2011 - BMI View: Despite the threat of austerity measures, the Swiss government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the patent cliff, we expect Switzerland to remain attractive to innovative drugmakers. Furthermore, per capita spending is high, there is a sizeable pensionable population and regulations are transparent - factors BMI believes will continue to bring in substantial income for companies operating in the country.

Headline Expenditure Projections

* Pharmaceuticals: CHF5.98bn (US$5.81bn) in 2010 to CHF5.99bn (US$5.81bn) in 2011; +0.1% growth in local currency terms and +1.35% in US dollar terms. Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
 * Healthcare: CHF60.01bn (US$57.58bn) in 2010 to CHF61.56bn (US$59.77bn) in 2011; 2.6% growth in local currency terms and 3.8% in US dollar terms. Our forecast has been revised up moderately from Q111 due to macroeconomic factors.
 * Medical devices: CHF5.11bn (US$4.90bn) in 2010 to CHF5.24bn (US$5.09bn) in 2011; 2.6% growth in local currency terms and 3.9% in US dollar terms. Our forecast has been revised down moderately due to analyst intervention.


Business Environment Rating: In BMI's Business Environment Ratings for Q211, Switzerland stands in top position, above Germany. Switzerland's score for the quarter stands at 68.6, well above the regional average of 63.8. Globally, the country is ranked in fourth position, below Canada and Japan and above Germany. However, BMI anticipates that Switzerland may fall down the world rankings in the medium to long term as large, high-growth emerging markets such as Brazil and China become more alluring to multinational drugmakers.

Key Trends & Developments

* Multinational drugmaker Novartis posted impressive full-year 2010 results, with sales topping US$50bn for the first time, increasing by 14% to US$50.62bn. Net income rose by 18% to US$9.97bn. The double-digit sales growth contrasts with other drugmakers, including Johnson & Johnson (J&J), Baxter and Amgen who reported single-digit turnover growth.


BMI Economic View: We expect the Swiss economy to show slower growth over the course of 2011, with real GDP forecast to expand by 1.8% compared with an estimated 2.6% increase in 2010. Such a slowdown will primarily be the result of the marked appreciation of the Swiss franc through H210, which we expect to weigh on export performance for the months ahead.

BMI Political View: With the Swiss franc surging 16% against the euro over the course of 2010, many in Switzerland have begun to voice concern over the potential threat posed to Swiss exporters and the resultant loss of jobs. While the current strength of Switzerland's currency may continue to be a cause of concern for many, especially as economic growth moderates in 2011, we do not expect to see this resulting in any associated threat to policy continuity or overall political stability.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/149602_switzerland_pharmaceuti...


Partial Table of Contents:

SWOT Analysis
- Switzerland Pharmaceuticals And Healthcare Industry SWOT
- Switzerland Political SWOT
- Switzerland Economic SWOT
- Switzerland Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Western Europe - Regional Pharmaceutical Business Environment Ratings for Q211
- Rewards
- Risks
Switzerland - Market Summary
Regulatory Regime
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Medicines
- Pricing Regime
- Recent Pricing System Developments
- Reimbursement Regime
Industry Developments
- Epidemiology
- Non-Communicable Disease
- Communicable Disease
- Health Insurance
- Healthcare Sector Financing
- Pharmaceutical Wholesale And Retail Sector
- Research And Development Sector
- Biotechnology Sector
- Clinical Trials
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Switzerland - GDP By Expenditure
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015
- Other Healthcare Data Forecasts
- Key Risks to BMI's Forecast Scenario
Competitive Landscape
- Pharmaceutical Industry
- Leading Local Pharmaceutical Companies According To Market Capitalisation
- Recent Company Developments
Company Monitor
- Indigenous Manufacturers
- Novartis
- Roche
- Merck-Serono
- Leading Multinational Manufacturers
- GlaxoSmithKline (GSK)
- Pfizer
- Sanofi-Aventis
- Merck & Co

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1496...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Health, Medical, Research
Tags:pharmaceutical, Healthcare, drug, roche, medicines, generic, novartis, disease, us721, lowered
Shortcut:prlog.org/11446726
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share